Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

Abstract

In this 24-week study, the addition of sitagliptin to ongoing, stable-dose insulin therapy with or without concomitant metformin improved glycaemic control and was generally well tolerated in patients with type 2 diabetes.